• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

减少不适当用药及多重用药国际组织(IGRIMUP):立场声明及十项行动建议

International Group for Reducing Inappropriate Medication Use & Polypharmacy (IGRIMUP): Position Statement and 10 Recommendations for Action.

作者信息

Mangin Dee, Bahat Gülistan, Golomb Beatrice A, Mallery Laurie Herzig, Moorhouse Paige, Onder Graziano, Petrovic Mirko, Garfinkel Doron

机构信息

Department of Family Medicine, Faculty of Health Sciences, McMaster University, 100 Main Street West, Hamilton, ON, Canada.

Department of General Practice, University of Otago, Christchurch, New Zealand.

出版信息

Drugs Aging. 2018 Jul;35(7):575-587. doi: 10.1007/s40266-018-0554-2.

DOI:10.1007/s40266-018-0554-2
PMID:30006810
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6061397/
Abstract

Globally, the number of drug prescriptions is increasing causing more adverse drug events, which is now a significant cause of mortality, morbidity, and disability that has reached epidemic proportions. The risk of adverse drug events is correlated to very old age, multiple co-morbidities, dementia, frailty, and limited life expectancy, with the major contributor being polypharmacy. Each characteristic alters the risk-benefit balance of medications, typically reducing anticipated benefits and amplifying risk. Current clinical guidelines are based on evidence proven in younger/healthier adult populations using a single disease model and their application to older adults with multimorbidity, in whom testing has not been conducted, yields a different risk-benefit prospect and makes inappropriate medication use and polypharmacy inevitable. Applying inappropriate clinical practice guidelines to older adults is antithetical to good healthcare, is likely to increase health inequity, and is associated with substantial negative clinical, economic, and social implications for health systems. The casualties are on the scale of a war or epidemic, yet are usually invisible in measures of healthcare quality and formal recommendations. Radical and rapid action is required to achieve a better quality of life for older populations and to remain true to the principles of medical professionalism and evidence-based medicine that place patients' interests and autonomy at the fore. This first International Group for Reducing Inappropriate Medication Use & Polypharmacy position statement briefly details the causes, consequences, and extent of inappropriate medication use and polypharmacy. This article outlines current strategies to reduce inappropriate medication use, provides evidence for their effect, and then proposes recommendations for moving forward with 10 recommendations for action and 12 recommendations for research. We conclude that an urgent integrated effort to reduce inappropriate medication use and polypharmacy should be a leading global target of the highest priority. The cornerstone of this position statement from the International Group for Reducing Inappropriate Medication Use & Polypharmacy is the understanding that without evidence of definite relevant benefit, when it comes to prescribing, for many older patients 'less is more'. This approach differs from most other current recommendations and guidance in medical care, as the focus is on what, when, and how to stop, rather than on when to start medications/interventions. Disrupting the framework that indiscriminately applies standard guidelines to older adults requires a new approach that better serves patients with multimorbidity. This transition requires a shift in medical education, research, and diagnostic frameworks, and re-examination of the measures used as quality indicators. In achieving this objective, we promote a return to some of the original concepts of evidence-based medicine: which considers scientific data (where it exists), clinical judgment, patient/family preference, and context. A shift is needed: from the current model that focuses on single conditions to one that simultaneously considers multiple conditions and patient priorities. This approach reframes the clinician's role as a professional providing care, rather than a disease technician.

摘要

在全球范围内,药物处方数量不断增加,导致更多药物不良事件,这已成为死亡率、发病率和残疾的一个重要原因,且已达到流行程度。药物不良事件的风险与高龄、多种合并症、痴呆、虚弱以及预期寿命有限相关,其中主要因素是多重用药。每种特征都会改变药物的风险效益平衡,通常会降低预期效益并放大风险。当前的临床指南基于在年轻/健康成年人群中经证据证明的单一疾病模型,将其应用于未进行过测试的患有多种合并症的老年人时,会产生不同的风险效益前景,并不可避免地导致用药不当和多重用药。将不适当的临床实践指南应用于老年人与优质医疗背道而驰,可能会加剧健康不平等,并对卫生系统产生重大的负面临床、经济和社会影响。这些伤亡规模如同战争或流行病,但在医疗质量衡量标准和正式建议中通常难以察觉。需要采取激进和迅速的行动,以提高老年人群的生活质量,并坚持将患者利益和自主权置于首位的医学专业精神和循证医学原则。这份由减少用药不当和多重用药国际小组发布的首份立场声明简要详述了用药不当和多重用药的原因、后果及程度。本文概述了减少用药不当的当前策略,提供了其效果的证据,然后提出了推进措施,包含10项行动建议和12项研究建议。我们得出结论,迫切需要开展综合努力以减少用药不当和多重用药,这应成为全球首要的最高优先目标。减少用药不当和多重用药国际小组这份立场声明的基石是,认识到在开药时,对于许多老年患者而言,若无明确相关益处的证据,“少即是多”。这种方法与当前医疗保健中的大多数其他建议和指导不同,因为重点在于停止用药的内容、时间和方式,而非开始用药/干预的时间。打破不加区分地将标准指南应用于老年人的框架需要一种新方法,以更好地服务患有多种合并症的患者。这种转变需要医学教育、研究和诊断框架的转变,以及对用作质量指标的措施进行重新审视。为实现这一目标,我们倡导回归循证医学的一些原始概念:即考虑科学数据(若有)、临床判断、患者/家庭偏好和背景。需要转变:从当前专注单一病症的模式转变为同时考虑多种病症和患者优先事项的模式。这种方法将临床医生的角色重新界定为提供护理的专业人员,而非疾病技术员。

相似文献

1
International Group for Reducing Inappropriate Medication Use & Polypharmacy (IGRIMUP): Position Statement and 10 Recommendations for Action.减少不适当用药及多重用药国际组织(IGRIMUP):立场声明及十项行动建议
Drugs Aging. 2018 Jul;35(7):575-587. doi: 10.1007/s40266-018-0554-2.
2
Polypharmacy in chronic diseases-Reduction of Inappropriate Medication and Adverse drug events in older populations by electronic Decision Support (PRIMA-eDS): study protocol for a randomized controlled trial.慢性病中的多重用药——通过电子决策支持减少老年人群不适当用药和药物不良事件(PRIMA-eDS):一项随机对照试验的研究方案
Trials. 2016 Jan 29;17:57. doi: 10.1186/s13063-016-1177-8.
3
Medication Appropriateness in Vulnerable Older Adults: Healthy Skepticism of Appropriate Polypharmacy.脆弱老年人的药物适宜性:对适当的多药疗法保持健康怀疑态度。
J Am Geriatr Soc. 2019 Jun;67(6):1123-1127. doi: 10.1111/jgs.15798. Epub 2019 Jan 30.
4
Adverse drug reactions in special populations - the elderly.特殊人群中的药物不良反应——老年人
Br J Clin Pharmacol. 2015 Oct;80(4):796-807. doi: 10.1111/bcp.12596. Epub 2015 May 22.
5
Methods to reduce prescribing errors in elderly patients with multimorbidity.减少老年多病患者处方错误的方法。
Clin Interv Aging. 2016 Jun 23;11:857-66. doi: 10.2147/CIA.S80280. eCollection 2016.
6
[RATIONAL DE-PRESCRIBING TO TREAT POLYPHARMACY - COUNTERING THE FIRST IATROGENIC EPIDEMIC].[合理减药治疗多重用药——应对首例医源性流行]
Harefuah. 2020 Sep;159(9):683-688.
7
Rationale and design of OPtimising thERapy to prevent Avoidable hospital admissions in Multimorbid older people (OPERAM): a cluster randomised controlled trial.多系统老年患者优化治疗以预防可避免住院(OPERAM):一项群组随机对照试验的基本原理和设计。
BMJ Open. 2019 Jun 3;9(6):e026769. doi: 10.1136/bmjopen-2018-026769.
8
Medication use in older patients and age-blind approach: narrative literature review (insufficient evidence on the efficacy and safety of drugs in older age, frequent use of PIMs and polypharmacy, and underuse of highly beneficial nonpharmacological strategies).老年患者的药物使用与年龄盲视方法:叙述性文献综述(关于老年人药物疗效和安全性的证据不足、不适当药物频繁使用和多重用药以及有益非药物策略使用不足)
Eur J Clin Pharmacol. 2019 Apr;75(4):451-466. doi: 10.1007/s00228-018-2603-5. Epub 2019 Jan 4.
9
Algorithm of medication review in frail older people: Focus on minimizing the use of high-risk medications.老年体弱患者用药审查算法:着重于尽量减少高风险药物的使用。
Geriatr Gerontol Int. 2016 Sep;16(9):1002-13. doi: 10.1111/ggi.12589. Epub 2015 Sep 3.
10
Family conferences and shared prioritisation to improve patient safety in the frail elderly (COFRAIL): study protocol of a cluster randomised intervention trial in primary care.家庭会议和共同优先级排序以改善虚弱老年人的患者安全(COFRAIL):初级保健中群组随机干预试验的研究方案。
Trials. 2020 Mar 20;21(1):285. doi: 10.1186/s13063-020-4182-x.

引用本文的文献

1
Identifying predictors of medication-related harm in older populations: a latent class analysis approach.识别老年人群中药物相关伤害的预测因素:一种潜在类别分析方法。
Age Ageing. 2025 Aug 1;54(8). doi: 10.1093/ageing/afaf227.
2
Sequential Patterns and Transition Timelines of Chronic Disease Comorbidities in Obesity: Evidence from the ELSA database.肥胖症中慢性病共病的序列模式和转变时间线:来自ELSA数据库的证据
Res Sq. 2025 Aug 13:rs.3.rs-7020515. doi: 10.21203/rs.3.rs-7020515/v1.
3
Factors associated with psychotropic drugs use in older adults hospitalized in clinical and surgical wards of a university hospital.

本文引用的文献

1
Poly-de-prescribing to treat polypharmacy: efficacy and safety.通过减少多重用药来治疗多重用药:疗效与安全性
Ther Adv Drug Saf. 2018 Jan;9(1):25-43. doi: 10.1177/2042098617736192. Epub 2017 Oct 27.
2
Effect of Statin Treatment vs Usual Care on Primary Cardiovascular Prevention Among Older Adults: The ALLHAT-LLT Randomized Clinical Trial.他汀类药物治疗与常规治疗对老年人原发性心血管预防的影响:ALLHAT-LLT随机临床试验
JAMA Intern Med. 2017 Jul 1;177(7):955-965. doi: 10.1001/jamainternmed.2017.1442.
3
Effects of workload, work complexity, and repeated alerts on alert fatigue in a clinical decision support system.
某大学医院临床和外科病房住院老年患者使用精神药物的相关因素。
Dement Neuropsychol. 2025 Jul 11;19:e20240228. doi: 10.1590/1980-5764-DN-2024-0228. eCollection 2025.
4
Identification of the Potential Pharmacotherapeutic Risk in Hospitalized Geriatric Patients.识别老年住院患者潜在的药物治疗风险。
Cureus. 2025 Mar 30;17(3):e81485. doi: 10.7759/cureus.81485. eCollection 2025 Mar.
5
The co-occurrence of multimorbidity and polypharmacy among middle-aged and older adults in Canada: A cross-sectional study using the Canadian Longitudinal Study on Aging (CLSA) and the Canadian Primary Care Sentinel Surveillance Network (CPCSSN).加拿大中老年人多重疾病与多种药物联合使用的共存情况:一项使用加拿大老龄化纵向研究(CLSA)和加拿大初级保健哨兵监测网络(CPCSSN)的横断面研究。
PLoS One. 2025 Jan 15;20(1):e0312873. doi: 10.1371/journal.pone.0312873. eCollection 2025.
6
A Time-varying Analysis of General Practice Prescribing in the COVID-19 Era: Lessons from Prescription Dynamics in a Pandemic.新冠疫情时代全科医疗处方的时变分析:大流行中处方动态的经验教训
In Vivo. 2025 Jan-Feb;39(1):498-508. doi: 10.21873/invivo.13854.
7
Prevalence of Value-Based Care for Older People with Dementia Likely to Be Nearing End of Life: A Hospital Retrospective Cohort.对可能处于生命末期的老年痴呆症患者实施基于价值的护理的患病率:一项医院回顾性队列研究
Healthcare (Basel). 2024 Nov 27;12(23):2382. doi: 10.3390/healthcare12232382.
8
Characteristics of the current situation of drug use in elderly patients with chronic diseases in Chongqing: A cross-sectional survey.重庆老年慢性病患者药物使用现状特征:一项横断面调查。
Medicine (Baltimore). 2024 Nov 15;103(46):e40470. doi: 10.1097/MD.0000000000040470.
9
Desprescribing antihypertensives in older people in primary care: subgroup analysis of the MINOR randomised clinical trial.基层医疗中老年人停用抗高血压药物:MINOR随机临床试验的亚组分析
Int J Clin Pharm. 2025 Feb;47(1):53-59. doi: 10.1007/s11096-024-01805-y. Epub 2024 Nov 6.
10
PHARMACOVIGILANCE IN SERBIA: A TEN-YEAR PHARMACOEPIDEMIOLOGIC ANALYSIS.塞尔维亚的药物警戒:十年药物流行病学分析。
Acta Clin Croat. 2023 Nov;62(3):486-501. doi: 10.20471/acc.2023.62.03.11.
临床决策支持系统中工作量、工作复杂性及重复警报对警报疲劳的影响。
BMC Med Inform Decis Mak. 2017 Apr 10;17(1):36. doi: 10.1186/s12911-017-0430-8.
4
Deprescribing in older people.老年人的减药方案
Maturitas. 2016 Sep;91:115-34. doi: 10.1016/j.maturitas.2016.06.006. Epub 2016 Jun 18.
5
Medical error-the third leading cause of death in the US.医疗差错——美国第三大死因。
BMJ. 2016 May 3;353:i2139. doi: 10.1136/bmj.i2139.
6
Deprescribing in Frail Older People: A Randomised Controlled Trial.老年体弱患者的减药治疗:一项随机对照试验。
PLoS One. 2016 Mar 4;11(3):e0149984. doi: 10.1371/journal.pone.0149984. eCollection 2016.
7
VALFORTA: a randomised trial to validate the FORTA (Fit fOR The Aged) classification.VALFORTA:一项验证FORTA(适合老年人)分类的随机试验。
Age Ageing. 2016 Mar;45(2):262-7. doi: 10.1093/ageing/afv200. Epub 2016 Jan 18.
8
Routine deprescribing of chronic medications to combat polypharmacy.为应对多重用药问题而进行的慢性药物常规减停
Ther Adv Drug Saf. 2015 Dec;6(6):212-33. doi: 10.1177/2042098615613984.
9
American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults.美国老年医学会2015年更新的《老年人潜在不适当用药的Beers标准》
J Am Geriatr Soc. 2015 Nov;63(11):2227-46. doi: 10.1111/jgs.13702. Epub 2015 Oct 8.
10
What are priorities for deprescribing for elderly patients? Capturing the voice of practitioners: a modified delphi process.老年患者减药的优先事项有哪些?倾听从业者的声音:一种改良的德尔菲法。
PLoS One. 2015 Apr 7;10(4):e0122246. doi: 10.1371/journal.pone.0122246. eCollection 2015.